Mereo BioPharma Group plc

MREO · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$7,024-$14,616-$12,887-$7,046
Dep. & Amort.-$11$298$270$274
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$2,065$2,278$1,515
Change in WC$636-$843-$514$857
Other Non-Cash-$910$5,445$2,524-$5,020
Operating Cash Flow-$7,309-$7,651-$8,329-$9,420
Investing Activities
PP&E Inv.$0$0-$20$0
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$300$0-$300$0
Investing Cash Flow$300$0-$320$0
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$0$0$0$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0-$134$422-$40
Financing Cash Flow$0-$134$422-$40
Forex Effect-$418$1,427$908-$1,260
Net Chg. in Cash-$7,427-$6,358-$7,319-$10,720
Supplemental Information
Beg. Cash$56,125$62,483$69,802$80,522
End Cash$48,698$56,125$62,483$69,802
Free Cash Flow-$7,309-$7,651-$8,649-$9,420
Mereo BioPharma Group plc (MREO) Financial Statements & Key Stats | AlphaPilot